ID: ALA5192840

Max Phase: Preclinical

Molecular Formula: C43H49ClFN7O7

Molecular Weight: 830.36

Associated Items:

Representations

Canonical SMILES:  O=C(CCC(=O)N1CCN(C(=O)c2cc(Cc3n[nH]c(=O)c4ccccc34)ccc2F)CC1)NCCCCCCNC(=O)COc1ccc2c(c1)CCCN2C(=O)CCl

Standard InChI:  InChI=1S/C43H49ClFN7O7/c44-27-41(56)52-19-7-8-30-26-31(12-14-37(30)52)59-28-39(54)47-18-6-2-1-5-17-46-38(53)15-16-40(55)50-20-22-51(23-21-50)43(58)34-24-29(11-13-35(34)45)25-36-32-9-3-4-10-33(32)42(57)49-48-36/h3-4,9-14,24,26H,1-2,5-8,15-23,25,27-28H2,(H,46,53)(H,47,54)(H,49,57)

Standard InChI Key:  VLFLARUCKPTAQH-UHFFFAOYSA-N

Associated Targets(Human)

MDA-MB-436 532 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

CAPAN-1 772 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MDA-MB-468 9477 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MDA-MB-231 73002 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 830.36Molecular Weight (Monoisotopic): 829.3366AlogP: 4.11#Rotatable Bonds: 17
Polar Surface Area: 174.11Molecular Species: NEUTRALHBA: 8HBD: 3
#RO5 Violations: 1HBA (Lipinski): 14HBD (Lipinski): 3#RO5 Violations (Lipinski): 2
CX Acidic pKa: 9.96CX Basic pKa: CX LogP: 2.55CX LogD: 2.55
Aromatic Rings: 4Heavy Atoms: 59QED Weighted: 0.11Np Likeness Score: -1.39

References

1. Pu C, Tong Y, Liu Y, Lan S, Wang S, Yan G, Zhang H, Luo D, Ma X, Yu S, Huang Q, Deng R, Li R..  (2022)  Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer.,  236  [PMID:35430559] [10.1016/j.ejmech.2022.114321]

Source